Cingulate Tumbles on Wider-Than-Expected 4Q Loss

Dow Jones03-19

By Elias Schisgall

Shares of Cingulate fell after the biopharmaceutical company posted a wider-than-expected loss in the fourth quarter.

The stock was down 27%, at $8.55, midday Wednesday, but has more than doubled in value over the past year.

The company on Wednesday reported a loss of $6.3 million, compared with a loss of $6.2 million a year earlier.

The Kansas City, Kan., company's full-year loss came out to $22.4 million, wider than its 2024 loss of $16.6 million.

Analysts were expecting a fourth-quarter loss of $4.8 million and a full-year loss of $20.8 million.

Cingulate, which doesn't have any products on the market, reported no revenue for the year. The Food and Drug Administration is currently reviewing a New Drug Application for its lead candidate, CTx-1301, a treatment for attention-deficit/hyperactivity disorder.

The company received a notice of allowance for its U.S. patent application for CTx-1301 on Tuesday. The patent, upon issuance, would protect key elements of the drug's formulation and method of use through May 2042, the company said.

Cingulate said Wednesday that its cash on hand would support its capital needs late into the fourth quarter as it seeks approval for and prepares to commercialize CTx-1301. It ended 2025 with about $11 million in cash and cash equivalents, and received a $12 million private investment led by Falcon Creek Capital last month.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

March 18, 2026 12:56 ET (16:56 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620263988?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-19 00:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620263988","market":"sh","top_or_hot":-1,"title":"Cingulate Tumbles on Wider-Than-Expected 4Q Loss","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Cingulate fell after the biopharmaceutical company posted a wider-than-expected loss in the fourth quarter. \n</p>\n<p>\n  The stock was down 27%, at $8.55, midday Wednesday, but has more than doubled in value over the past year. \n</p>\n<p>\n  The company on Wednesday reported a loss of $6.3 million, compared with a loss of $6.2 million a year earlier. \n</p>\n<p>\n  The Kansas City, Kan., company's full-year loss came out to $22.4 million, wider than its 2024 loss of $16.6 million. \n</p>\n<p>\n  Analysts were expecting a fourth-quarter loss of $4.8 million and a full-year loss of $20.8 million. \n</p>\n<p>\n  Cingulate, which doesn't have any products on the market, reported no revenue for the year. The Food and Drug Administration is currently reviewing a New Drug Application for its lead candidate, CTx-1301, a treatment for attention-deficit/hyperactivity disorder. \n</p>\n<p>\n  The company received a notice of allowance for its U.S. patent application for CTx-1301 on Tuesday. The patent, upon issuance, would protect key elements of the drug's formulation and method of use through May 2042, the company said. \n</p>\n<p>\n  Cingulate said Wednesday that its cash on hand would support its capital needs late into the fourth quarter as it seeks approval for and prepares to commercialize CTx-1301. It ended 2025 with about $11 million in cash and cash equivalents, and received a $12 million private investment led by Falcon Creek Capital last month. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 18, 2026 12:56 ET (16:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cingulate Tumbles on Wider-Than-Expected 4Q Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCingulate Tumbles on Wider-Than-Expected 4Q Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-19 00:56</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Cingulate fell after the biopharmaceutical company posted a wider-than-expected loss in the fourth quarter. \n</p>\n<p>\n  The stock was down 27%, at $8.55, midday Wednesday, but has more than doubled in value over the past year. \n</p>\n<p>\n  The company on Wednesday reported a loss of $6.3 million, compared with a loss of $6.2 million a year earlier. \n</p>\n<p>\n  The Kansas City, Kan., company's full-year loss came out to $22.4 million, wider than its 2024 loss of $16.6 million. \n</p>\n<p>\n  Analysts were expecting a fourth-quarter loss of $4.8 million and a full-year loss of $20.8 million. \n</p>\n<p>\n  Cingulate, which doesn't have any products on the market, reported no revenue for the year. The Food and Drug Administration is currently reviewing a New Drug Application for its lead candidate, CTx-1301, a treatment for attention-deficit/hyperactivity disorder. \n</p>\n<p>\n  The company received a notice of allowance for its U.S. patent application for CTx-1301 on Tuesday. The patent, upon issuance, would protect key elements of the drug's formulation and method of use through May 2042, the company said. \n</p>\n<p>\n  Cingulate said Wednesday that its cash on hand would support its capital needs late into the fourth quarter as it seeks approval for and prepares to commercialize CTx-1301. It ended 2025 with about $11 million in cash and cash equivalents, and received a $12 million private investment led by Falcon Creek Capital last month. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 18, 2026 12:56 ET (16:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CING","symbol_name":"CINGULATE INC.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2620263988","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620263988","pubTimestamp":1773852960,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Cingulate fell after the biopharmaceutical company posted a wider-than-expected loss in the fourth quarter.The stock was down 27%, at $8.55, midday Wednesday, but has more than doubled in value over the past year.The company on Wednesday reported a loss of $6.3 million, compared with a loss of $6.2 million a year earlier.The Kansas City, Kan., company's full-year loss came out to $22.4 million, wider than its 2024 loss of $16.6 million.Analysts were expecting a fourth-quarter loss of $4.8 million and a full-year loss of $20.8 million.The company received a notice of allowance for its U.S. patent application for CTx-1301 on Tuesday. The patent, upon issuance, would protect key elements of the drug's formulation and method of use through May 2042, the company said.Cingulate said Wednesday that its cash on hand would support its capital needs late into the fourth quarter as it seeks approval for and prepares to commercialize CTx-1301. It ended 2025 with about $11 million in cash","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CING":"CINGULATE INC.","BK4007":"制药"},"translate_title":"Cingulate因第四季度亏损超出预期而暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CING":0.9},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Shares of Cingulate fell after the biopharmaceutical company posted a wider-than-expected loss in the fourth quarter. \n\n\n  The stock was down 27%, at $8.55, midday Wednesday, but has more than doubled in value over the past year. \n\n\n  The company on Wednesday reported a loss of $6.3 million, compared with a loss of $6.2 million a year earlier. \n\n\n  The Kansas City, Kan., company's full-year loss came out to $22.4 million, wider than its 2024 loss of $16.6 million. \n\n\n  Analysts were expecting a fourth-quarter loss of $4.8 million and a full-year loss of $20.8 million. \n\n\n  Cingulate, which doesn't have any products on the market, reported no revenue for the year. The Food and Drug Administration is currently reviewing a New Drug Application for its lead candidate, CTx-1301, a treatment for attention-deficit/hyperactivity disorder. \n\n\n  The company received a notice of allowance for its U.S. patent application for CTx-1301 on Tuesday. The patent, upon issuance, would protect key elements of the drug's formulation and method of use through May 2042, the company said. \n\n\n  Cingulate said Wednesday that its cash on hand would support its capital needs late into the fourth quarter as it seeks approval for and prepares to commercialize CTx-1301. It ended 2025 with about $11 million in cash and cash equivalents, and received a $12 million private investment led by Falcon Creek Capital last month. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 18, 2026 12:56 ET (16:56 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620263988","isCrawlerRequest":true}